First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009

The Lancet Oncology

Volumn 10, Issue 11, 2009, Pages 1102-1110

  Soo, Ross A ^a   Anderson, Benjamin O ^b   Cho, Byoung Chul ^c   Yang, Chih Hsin ^d   Liao, Meilin ^e   Lim, Wan Teck ^f   Goldstraw, Peter ^g   Mok, Tony S ^h  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Yonsei University College of Medicine   (South Korea)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e SHANGHAI CHEST HOSPITAL   (China)

^f DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^g ROYAL BROMPTON HOSPITAL   (United Kingdom)

^h CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MITOMYCIN; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; TAXANE DERIVATIVE; TENIPOSIDE; VINBLASTINE; VINCA ALKALOID; VINDESINE;

ADVANCED CANCER; ASIA; CANCER SURVIVAL; CLINICAL TRIAL; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG RESPONSE; ELDERLY CARE; HEALTH CARE SYSTEM; HEALTH PROGRAM; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RESOURCE ALLOCATION; REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIA; CARCINOMA, NON-SMALL-CELL LUNG; CONGRESSES AS TOPIC; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; DRUG COSTS; EVIDENCE-BASED MEDICINE; GUIDELINE ADHERENCE; HEALTH CARE COSTS; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HUMANS; LUNG NEOPLASMS; MEDICAL ONCOLOGY; NEOPLASM STAGING; TREATMENT OUTCOME;

EID: 71549117595     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70238-4     Document Type: Review

References (72)

1. Garcia M., Jemal A., Ward E.M., et al. Global cancer facts & figures 2007 (2007), American Cancer Society, Atlanta, GA
2. Warner K.E. The role of research in international tobacco control. Am J Public Health 95 (2005) 976-984
3. D'Addario G., and Felip E. ESMO Guidelines Working Group. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20 suppl 4 (2009) 68-70
4. Socinski M.A., Crowell R., Hensing T.E., et al. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132 3 suppl (2007) 277-289
5. Ettinger D.S., Bepler G., and Bueno R. Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 4 (2006) 548-582
6. Guyatt G., Baumann M., Pauker S., et al. Addressing resource allocation issues in recommendations from clinical practice guideline panels: suggestions from an American College of Chest Physicians task force. Chest 129 (2006) 182-187
7. Anderson B.O., Yip C.-H., Smith R.A., et al. Guideline implementation for breast healthcare in low-income and middle-income countries. Cancer 113 8 suppl (2008) 2221-2243
8. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311 (1995) 899-909
9. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 26 (2008) 4617-4625
10. Ranson M., Davidson N., Nicolson M., et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 92 (2000) 1074-1080
11. Anderson H., Hopwood P., Stephens R.J., et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer: a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Br J Cancer 83 (2000) 447-453
12. Roszkowski K., Pluzanska A., Krzakowski M., et al. A multicenter, randomized, phase 3 study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 27 (2000) 145-157
13. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91 (1999) 66-72
14. Lilenbaum R.C., Langenberg P., and Dickersin K. Single agent versus combination chemotherapy. Cancer 82 (1998) 116-126
15. Marino P., Preatoni A., Cantoni A., et al. Single-agent chemotherapy versus combination chemotherapy in advanced non-small cell lung cancer: a quality and meta-analysis study. Lung Cancer 13 (1995) 1-12
16. Delbaldo C., Michiels S., Syz N., et al. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 292 (2004) 470-484
17. Paccagnella A., Oniga F., Bearz A., et al. Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase 2-3 study. J Clin Oncol 24 (2006) 681-687
18. Comella P., Filippelli G., De Cataldis G., et al. Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase 3 randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101). Ann Oncol 18 (2007) 324-330
19. Schiller J.H., Harrington D., Belani C., et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346 (2002) 92-98
20. Scagliotti G.V., De Marinis F., Rinaldi M., et al. Phase 3 randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20 (2002) 4285-4291
21. Ohe Y., Ohashi Y., Kubota K., et al. Randomized phase 3 study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-arm cooperative study in Japan. Ann Oncol 18 (2007) 317-323
22. Gandara D.R., Ohe Y., Kubota K., et al. Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): a model for prospective comparison of cooperative group trials. Proc Am Soc Clin Oncol 22 (2004) 618
23. Ardizzoni A., Boni L., Tiseo M., et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 99 (2007) 847-857
24. Rajeswaran A., Trojan A., Burnand B., and Giannelli M. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer 59 (2008) 1-11
25. Scagliotti G.V., Parikh P., von Pawel J., et al. Phase 3 study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26 (2008) 3543-3551
26. Belani C.P., Brodowicz T., Ciuleanu T., et al. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: a randomized phase 3 study in advanced non-small cell lung cancer (NSCLC) (abstract). J Clin Oncol 27 (2009) 18s
27. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 355 (2006) 2542-2550
28. Reck M., von Pawel J., Zatloukal P., et al. Phase 3 trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27 (2009) 1227-1234
29. Pirker R., Pereira J.R., Szczesna A., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase 3 trial. Lancet 373 (2009) 525-531
30. Giaccone G., Herbst R.S., Manegold C., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase 3 trial-INTACT 1. J Clin Oncol 22 (2004) 777-784
31. Herbst R.S., Giaccone G., Schiller J.H., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase 3 trial, INTACT 2. J Clin Oncol 22 (2004) 785-794
32. Herbst R.S., Prager D., Hermann R., et al. TRIBUTE: a phase 3 trial of erlotinib (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer. J Clin Oncol 23 (2005) 5892-5899
33. Gatzemeier U., Pluzanska A., Szczesna A., et al. Phase 3 study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25 (2007) 1545-1552
34. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
35. Shepherd F.A., Pereira J.R., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
36. Thatcher N., Chang A., Parikh P., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 (2005) 1527-1537
37. Shigematsu H., Lin L., Takahashi T., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97 (2005) 339-346
38. Mok T., Wu Y.-L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361 (2009) 947-957
39. Smith I.E., O'Brien M.E., Talbot D.C., et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 19 (2001) 1336-1343
40. Socinski M.A., Schell M.J., Peterman A., et al. Phase 3 trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 20 (2002) 1335-1343
41. von Plessen C., Bergman B., Andresen O., et al. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer 95 (2006) 966-973
42. Brodowicz T., Krzakowski M., Zwitter M., et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase 3 trial. Lung Cancer 52 (2006) 155-163
43. Park J.O., Kim S.W., Ahn J.S., et al. Phase 3 trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol 25 (2007) 5233-5239
44. Soon Y.Y., Stockler M.R., Askie L.M., and Boyer M.J. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol 27 (2009) 3277-3283
45. Lima J.P., dos Santos L.V., Sasse E.C., and Sasse A.D. Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: a systematic review with meta-analysis. Eur J Cancer 45 (2009) 601-607
46. Westeel V., Quoix E., Moro-Sibilot D., et al. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst 97 (2005) 499-506
47. Sculier J.P., Lafitte J.J., Lecomte J., et al. A phase 3 randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancer. Ann Oncol 18 (2007) 1037-1042
48. Fidias P.M., Dakhil S.R., Lyss A.P., et al. Phase 3 study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 27 (2009) 591-598
49. Hida T., Okamoto I., Kashii T., et al. Randomized phase 3 study of platinum-doublet chemotherapy followed by gefitinib versus continued platinum-doublet chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): Results of West Japan Thoracic Oncology Group trial (WJTOG0203) (abstract). J Clin Oncol 26 (2008) 427s
50. Cappuzzo F., Ciuleanu T., Stelmakh L., et al. SATURN: a double-blind, randomized, phase 3 study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC (abstract). J Clin Oncol 27 (2009) 15
51. Miller V.A., O'Connor P., Soh C., et al. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) (abstract). J Clin Oncol 27 (2009) 18
52. Gridelli C., Perrone F., Gallo C., et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase 3 randomized trial. J Natl Cancer Inst 95 (2003) 362-372
53. Freudenberg L.S., Rosenbaum S.J., Beyer T., Bockisch A., and Antoch G. PET versus PET/CT dual-modality imaging in evaluation of lung cancer. Radiol Clin North Am 45 (2007) 639-644
54. Cavalli F. The World Cancer Declaration: a roadmap for change. Lancet Oncol 9 (2008) 810-811
55. Macbeth F.R., Abratt R.P., Cho K.H., Stephens R.J., Jeremic B., and International Atomic Energy Agency. Lung cancer management in limited resource settings: guidelines for appropriate good care. Radiother Oncol 82 (2007) 123-131
56. Groot M.T., Baltussen R., Uyl-de Groot C.A., Anderson B.O., and Hortobagyi G.N. Costs and health effects of breast cancer interventions in epidemiologically different regions of Africa, North America, and Asia. Breast J 12 suppl 1 (2006) 81-90
57. Chouaid C., Atsou K., Hejblum G., and Vergnenegre A. Economics of treatments for non-small cell lung cancer. Pharmacoeconomics 27 (2009) 113-125
58. Carlson J.J., Veenstra D.L., and Ramsey S.D. Pharmacoeconomic evaluations in the treatment of non-small cell lung cancer. Drugs 68 (2008) 1105-1113
59. Ullrich A., Waxman A., da Costa e Silva V.L., et al. Cancer prevention in the political arena: the WHO perspective. Ann Oncol 15 suppl 4 (2004) 249-256
60. Ngoma T. World Health Organization cancer priorities in developing countries. Ann Oncol 17 suppl 8 (2006) 9-14
61. Seffrin J.R. Cancer control as a human right. Lancet Oncol 9 (2008) 409-411
62. Kanavos P. The rising burden of cancer in the developing world. Ann Oncol 17 suppl 8 (2006) 15-23
63. Roemer R., Taylor A., and Lariviere J. Origins of the WHO framework convention on tobacco control. Am J Public Health 95 (2005) 936-938
64. Program in Development-ASCO Cancer Foundation. http://www.asco.org/TACF/International+Outreach/Programs+in+Development (accessed April 27, 2009).
65. Hansen H.H., Bajorin D.F., Muss H.B., et al. Recommendations for a global core curriculum in medical oncology. J Clin Oncol 22 (2004) 4616-4625
66. International Union Against Cancer: technology transfer. http://www.uicc.org/index.php?option=com_content&task=view&id=14 262&Itemid=185 (accessed April 27, 2009).
67. Rawlins M. Paying for modern cancer care-a global perspective. Lancet Oncol 8 (2007) 749-751
68. WHO Model List of Essential Medicines (2007). http://www.who.int/medicines/publications/08_ENGLISH_indexFINAL_EML15.pd f (accessed April 21, 2009).
69. The Max Foundation. http://www.themaxfoundation.org/GIPAP/Default.aspx (accessed April 27, 2009).
70. Bukachi F., and Pakenham-Walsh N. Information technology for health in developing countries. Chest 132 (2007) 1624-1630
71. WHO. HINARI Access to Research Initiative. www.who.int/hinari/en/ (accessed April 27, 2009).
72. Howard S.C., Pedrosa M., Lins M., et al. Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a resource-poor area. JAMA 291 (2004) 2471-2475